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Next-generation sequencing-based assays to detect gene regulatory elements are enabling the analysis of
individual-to-individual and allele-specific variation of chromatin status and transcription factor binding in
humans. Recently, a number of studies have explored this area, using lymphoblastoid cell lines. Around
10% of chromatin sites show either individual-level differences or allele-specific behavior. Future studies
are likely to be limited by cell line accessibility, meaning that white-bloodcell-based studies are likely to con-
tinue to be the main source of samples. A detailed understanding of the relationship between normal genetic
variation and chromatin variation can shed light on how polymorphisms in non-coding regions in the human
genome might underlie phenotypic variation and disease.
INTRODUCTION
The advent of next-generation sequencing (1) has revolutio-
nized research in gene regulation. The low cost of obtaining
genome-wide information for transcription factor binding,
histone modifications and chromatin status has enabled the
extensive study of various regulatory features of different
cell types in a variety of organisms (2–4). Systematic projects
such as ENCODE (5), the human Epigenome Roadmap (now
expanding into the International Human Epigenome Consor-
tium) (6) and the fly and worm modENCODE projects (7)
have focussed on defining the chromatin state, how it varies
between different cell types, how such stable ‘cellular
memory’ endpoints differ and how, during development,
such cellular memory is determined.
Most of these studies to date have characterized the chroma-
tin state for a series of specific cell types, each from only a
single individual and averaged over both chromosomes in
the cell. However, individuals are likely to differ at some
level in their chromatin state for a particular cell type, and
each cell contains pairs of homologous chromosomes whose
chromatin structure and expression status are not necessarily
identical. Heterozygous base pairs present between homolo-
gous chromosomes enable the detection of allele-specific
signals in sequence-based assays (Fig. 1). Recent studies
have found that gene expression and chromatin structure do
indeed differ between homologous chromosomes in the same
cell, and accordingly, between the same cell types obtained
from different individuals (8–10). Learning the relationship
between genetic variation and variation in chromatin offers
the potential to bridge the gap between genome-wide associ-
ation studies (GWASs) that have linked many diseases to
single nucleotide polymorphisms (SNPs) and an understanding
of how such polymorphisms, most of which are found in non-
coding regions, can underlie phenotypic variation. Here, we
review the relevant studies to date, focussing on individual
and allele-specific chromatin rather than gene expression at
the level of RNA, and outline key technical considerations
and potential future directions for detecting individual and
allele-specific differences in chromatin organization.
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ASSAYS USED TO DETECT INDIVIDUAL-SPECIFIC
AND ALLELE-SPECIFIC CHROMATIN
SIGNATURES
A number of assays analyze chromatin state and identify
active gene regulatory elements genome-wide including
mapping DNaseI hypersensitive sites (DHSs) (11,12),
formaldehyde-assisted isolation of regulatory elements
(FAIRE) (13) and chromatin immunoprecipitation (ChIP)
(reviewed in 14). Figure 2 schematically shows how these
assays work. DHSs and FAIRE identify active regulatory
elements through detection of nucleosome-free regions,
whereas ChIP identifies specific transcription factor-binding
sites and presence of specific histone variants and histone
tail modifications. One can also study DNA methylation
using a number of methods (15), but that is beyond the
scope of this review and will not be discussed here. DHSs,
FAIRE and ChIP are distinct methods and the strengths and
limitations of using these assays in large population studies
are further discussed below.
DHSs represent regions of the genome where nucleosomes
have been displaced by transcription factors, making them
hypersensitive to DNaseI digestion. These regions are com-
monly described as ‘open’ chromatin, whereas the remaining
regions are ‘closed’. DHSs can robustly identify all different
types of active regulatory elements, including promoters,
enhancers, silencers, insulators and locus control regions.
While DHSs do not directly reveal which transcription
factor(s) are binding to each region, it does identify in a
general sense where the functional regulatory elements of
the genome are and whether they are open or closed across
diverse cell types, as well as within the same cell type
across many individuals.
FAIRE uses formaldehyde to biochemically separate DNA
that is packaged in nucleosomes from DNA that is bound by
non-nucleosomal proteins like transcription factors. Although
FAIRE is also enriching for open chromatin regions, it is
methodologically independent from DNaseI experiments and
therefore complementary. It is also comprehensive in that it
is an inherently genome-wide method that enriches for all
known classes of regulatory elements. Since FAIRE uses for-
maldehyde, a distinct advantage of this method is that it can
readily be used on fixed frozen tissues.
ChIP precisely determines the location of specific
DNA-associated proteins, histone variants and histone modifi-
cations within the genome, which is more informative than
general open chromatin data generated by DNaseI and
FAIRE. Specific factors, variants and/or modifications can
be targeted for analysis depending on the disease or suspected
gene involvement. While ChIP provides very specific infor-
mation about factor location, this assay is limited to factors
that have high-quality ChIP-grade antibodies and only one
factor is tested per experiment. Tagged versions of proteins
are an alternative option for cultured cells, but not suitable
for studying primary cell types or tissues.
The original implementations of these methods to study
chromatin involved detection of specific signals using
Southern blots, PCR or microarray hybridization, but all of
these methods have now been adapted to use next-generation
sequencing (DNase-seq, FAIRE-seq and ChIP-seq), which
in addition to providing a genome-wide readout, also
offers the opportunity to resolve allele-specific signals.
DNaseI, FAIRE and ChIP experiments generate libraries of
DNA fragments that are enriched in genomic regions corre-
sponding to open chromatin (DNaseI and FAIRE), or that
were cross-linked to targets of specific antibodies (ChIP).
These fragments will vary in size depending on the protocol,
but all are amenable to construction of sequencing libraries
using any of the currently available platforms. Each sequen-
cing experiment generates tens of millions of short sequence
reads that provide a sampling of the DNA in the constructed
library.
To determine regions of open chromatin, ChIP targets and
allele-specific biology, sequence reads must be aligned to a
reference genomic sequence. A large and growing number
of software packages are available to align reads and further
process these data (16–18). The short length of the sequence
reads, the repetitive nature of large mammalian genomes and
the incompleteness of specific types of regions within the
reference genome create challenges that must be carefully
considered, particularly for detection of allele-specific
signals at heterozygous SNPs because of the effect of apparent
mismatches on shorter reads as described below. Paired-end
sequencing of both ends of an enriched DNA fragment can
alleviate some of the inherent uncertainty of aligning reads
to the reference genome.
Figure 1. This figure shows three different types of experiments for assaying
differences in chromatin state in equivalent and different cell types. The blue
lines represent the genome sequence in a region; the blue and maroon peaks
show regions of enrichment from a chromatin-based assay, such as DNaseI,
FAIRE or ChIP-seq. The top panel shows results from an idealized experiment
between two different cell lines, often with considerable differences. The
middle panel shows an experiment between two different individuals which
differ in a smaller proportion of peaks, and often, though not always, this is
associated with local genetic changes, such as an SNP difference (shown as
black arrows with the genotypes G/G and T/T nearby). The bottom panel
shows an experiment on a single individual in which the presence of a hetero-
zygote SNP allows the relative proportion of reads contributed by each allele
to be known, as illustrated in the pie chart.
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CELL TYPES AMENABLE TO STUDYING
DIFFERENCES IN CHROMATIN AMONG
INDIVIDUALS
Chromatin signatures vary considerably between different cell
types, so when exploring inter-individual differences, it is
important to acquire the identical cell type from each individ-
ual. Furthermore, for disease-related studies, it would be ideal
to study disease-relevant tissues. However, the heterogeneity
of cells within intact tissues, and even sub-compartments
within tissues, makes acquiring such pure cell types especially
challenging. Obtaining intact tissue from humans also often
requires invasive procedures that typically take place during
medical intervention, meaning that the tissue obtained may
be affected by an unrelated medical condition, further compli-
cating downstream analyses. Organ donations from cadavers
are a valuable source of tissues, but often these tissues are sub-
optimal for analysis due to the degradation that may take place
between death and tissue acquisition.
Because of these constraints, many studies have focussed on
readily accessible white blood cell lineages. While these cells
are not ideal for studying diseases unrelated to immune cell
function, one distinct advantage is that they can be sorted
using cell surface markers to isolate relatively pure sub-
populations of cells in high numbers. However, there are chal-
lenges with this procedure as well. For example, sorting cells
using positive selection often activates cells, which may con-
found analyses depending on the immune cell type, health of
the individual at the time of blood draw and previous environ-
mental exposures. Using negative selection, which avoids acti-
vating the cells, to isolate cell populations is sometimes
possible, but cell numbers and purity are often sub-optimal.
Even populations of blood cell lineages considered ‘pure’ by
sorting are often made up of additional known and unknown
sub-populations of cells, which likely fluctuate within individ-
uals on a daily basis. Further studies are required to determine
whether other more homogenous primary blood cell popu-
lations, for example neutrophils, might be better suited for
large population studies. Regardless, it remains a challenge
to find a readily accessible, perfectly matched cell type from
a large population of individuals.
Currently, the largest set of accessible cells from different
individuals is based on Epstein–Barr-virus-transformed
white blood cells, called ‘lymphoblastoid lines’. One key
advantage of these cells for analyzing variation in chromatin
is that they have been extensively genotyped by the HapMap
and 1000 Genomes project, and archived lines are readily
available. They are derived from a mixed population of
naive and memory B-cells that likely differ between individ-
uals at the time of sampling. Despite this, the studies described
below show that there are clear correlations between specific
DNA sequence variants and the chromatin readouts. This indi-
cates that at least some of the differences are due to individual-
specific genetics, rather than variations in isolation techniques
or cell-type heterogeneity. On the other hand, the effects of
genetic variation and allele-specific gene expression can
occur in a tissue- or cell-type-specific manner (8,19,20), indi-
cating that results obtained from studying a single cell type
may not be universally applicable to all cell types. The other
readily accessible cell type is skin fibroblasts, which from a
small skin biopsy can be expanded in culture to large cell
numbers.
Another potential approach for studying alternative cell
types is to use induced pluripotent stem cells (iPSCs)
(reviewed in 21), where cells from specific individuals can
be reprogramed into pluripotent cells that can be differentiated
into many cell types. However, it is possible that a residual
epigenetic memory of the parental cell type is retained
through reprograming (22). Matched primary and iPSC-
derived cell types analyzed in reasonably large numbers will
be needed before one can assess how well, if at all, iPSC-based
cell types could be used for exploring inter-individual chroma-
tin differences. In addition, advances in iPSC manipulation,
such as differentiating iPS cells into pure populations of
disease-relevant cell types will be needed for this technology
to be used routinely.
Figure 2. A schematic diagram of three chromatin assays. The blue cylinders represent the core histones, around which the DNA is wrapped. The pentagon
represents a bound transcription factor (TF) which has displaced histones in a particular region; this region is described as ‘open chromatin’. The FAIRE
assay enriches for such open chromatin regions by differential solubility in phenol. The DNaseI assay utilizes the fact that regions of the open chromatin
are much more susceptible to DNaseI digestion. The ChIP assay uses a specific antibody to enrich for DNA regions binding to a specific transcription factor
or a modified histone.
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STUDIES OF VARIATION IN HUMAN CHROMATIN
SIGNATURES AMONG ALLELES AND
INDIVIDUALS
For assaying individual-specific variation, data from the same
cell or tissue type from different individuals are required,
ideally processed under the same conditions. For assaying
allele-specific variation, the underlying genotype must
additionally be known so that it can be associated with any
observed allele-specific differences in binding or chromatin.
Allele-specific transcription factor binding has been assayed
by reading out the results of ChIP by microarray hybridization
for RNA pol II and various histone modifications on SNP gen-
otyping arrays (23,24). One limitation of these studies is that
only heterozygous sites that were preselected for inclusion
on the array could be assayed, and of these, only the poly-
morphisms that overlapped a binding site were informative.
Thus, only a small number of allele-specific-binding sites
could be identified. ChIP-seq can be used to detect allele-
specific differences in factor binding or chromatin at all het-
erozygous sites in a single individual by analyzing the two
alleles separately. Indeed, the earliest ChIP-seq studies recog-
nized this feature of data from these experiments and ident-
ified several instances of histone modifications where the
signal from the two alleles covering a heterozygous site was
significantly different (25).
These early studies were performed in cell lines that were
not comprehensively and independently genotyped, thus limit-
ing the number of sites at which the allele-specificity of each
histone modification could be assayed. The availability of
comprehensive genotyping data from the 1000 Genomes
Project for a large set of lymphoblastoid cell lines vastly
increases the number of sites with an informative underlying
genotype. Two recent studies have taken advantage of the com-
bination of next generation sequencing and genotype infor-
mation to examine the extent and nature of allele-specific and
individual-specific transcription factor binding and chromatin
in lymphoblastoid cell lines. McDaniell et al. (9) measured
allele-specific binding of the multifunctional transcription
factor CTCF as well as individual-specific DHS open chromatin
sites for six individuals from two parent–child trios. About
10% of DHS sites were found to be individual-specific, with
patterns of occurrence that were consistent with inheritance.
In the analysis of allele-specific signals, they observed that, in
general, sequence reads that contained the reference genome
allele tended to align at higher rates compared with sequence
reads containing the alternate allele, generating an artifactual
bias that can have the appearance of allele-specific binding.
This reference bias has also been noted in similar analyses per-
formed with RNA-seq data (26) and precautions must be taken
to account and correct for it during the sequence alignment
process. After the appropriate corrections, McDaniell et al.
found that approximately 11% of assayable CTCF-binding
sites in the human genome were allele-specific. Importantly,
the direction of the allele-specificity was highly correlated
across individuals that shared the same heterozygous genotype,
and the relative strengths of the signal in homozygous parents
were generally concordant with the allele-specificity at the
corresponding heterozygous site in the child. Moreover, poly-
morphisms that were most likely to show allele-specific
binding generally corresponded to highly conserved nucleotide
positions in the CTCF-binding motif. These observations indi-
cated that allele-specificity of CTCF binding was genetic rather
than epigenetic or stochastic in origin and could be inherited.
In a contemporaneous study, Kasowski et al. (10) examined
individual-specific and allele-specific differences in the
binding of the transcription factor NF-kB and RNA polymer-
ase II across 10 lymphoblastoid cells that were also genotyped
by the 1000 Genomes Project. Their approach was to first
identify individual-specific binding events, and then relate
these to the underlying genotype, thereby avoiding alignment
bias issues. This study found that a significant proportion of
individual differences in binding was due to underlying
SNPs or structural variation such as deletions affecting the
NF-kB-binding motif or the TATA element in the promoter
in the case of variation in RNA pol II binding. Interestingly,
the number of SNPs in a factor’s defined binding regions
was proportional to the extent of the observed binding differ-
ences. They also showed that this variation in binding was cor-
related with differences in gene expression, indicating a direct
functional outcome of this genetic variation. Additionally,
Kasowski et al. analyzed differences in binding between
humans and chimpanzees and showed that the inter-individual
differences between humans were less than inter-species
differences.
Perhaps, the most important contribution of these studies is
the demonstration that such individual-specific and allele-
specific differences exist in transcription factor binding and
open chromatin, that they can be reliably measured, that
they have consequences on downstream events such as
expression and that at least some proportion of these differ-
ences is due to heritable genetic variation.
RELEVANCE OF ALLELE-SPECIFIC AND
INDIVIDUAL-SPECIFIC CHROMATIN STUDIES
TO HUMAN DISEASE
GWASs have linked hundreds of specific SNPs to disease risk,
but in most cases the causal connection between the SNPs and
the phenotype is unknown, partly because most of these SNPs
are non-coding. These SNPs are often assumed to be regulat-
ory in function, but our annotation of regulatory elements is
far from complete. Moreover, the effect of nucleotide vari-
ation on the activity of those regulatory elements has been
far harder to understand, leading to difficulties in designing
further experiments. It is likely that much of the nucleotide
variation causally linked to human disease (and a multitude
of other phenotypic traits) does indeed occur in regulatory
elements. We hypothesize that these causal variants are man-
ifested as changes in chromatin organization caused either by
the influence of nucleotide sequence on DNA packaging
directly, or by affecting the binding of regulatory factors to
DNA. For example, a polymorphism associated with type 2
diabetes differentially affects open chromatin in pancreatic
islet cells as detected by the FAIRE assay (27). A systematic
effort to uncover the relationship between genetic variation in
humans on the one hand and variation in chromatin structure
and transcription factor binding on the other can dramatically
narrow our search for the genetic cause of increased disease
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risk, and simultaneously will provide insight into disease
mechanism. Detailed analysis of allele-specific and individual-
specific chromatin signatures across a broad range of
genotyped individuals, as well in disease patients and
normal controls, can help bridge the gap between our ability
to detect genetic variation linked to disease and our ability
to explain how that variation causes disease.
FUTURE PROSPECTS
The ability to cost-effectively analyze a variety of chromatin-
related features is already fueling a revolution in chromatin
and gene regulation studies, in particular associated with
development and cell identity. The recent studies described
above show that such differences exist and are biologically rel-
evant. However, there are still considerable hurdles to over-
come before such profiling can be deployed on a large scale,
in particular in the context of disease studies.
A major issue will be sample acquisition, handling and
purity. The prevalence and easy access of lymphoblastoid
cell lines, which are present in many disease-relevant
cohorts and a number of prospective studies [for example,
ALSPAC (28)] means that differences measured in these cell
lines would be applicable to a large set of existing studies.
Owing to the long-term logistical planning for disease
cohorts, it is worth considering banking other cell types (e.g.
fibroblasts) and potentially primary cultures or stable deriva-
tives of primary cultures, such as frozen, fixed chromatin prep-
arations in current or future cohorts. Cell types most relevant
to a disease would be ideal, but that must be balanced with
cost, accessibility of cells and, in many cases, a requirement
for invasive procedures to obtain the appropriate tissue. It
seems likely that as with eQTLs, a proportion of chromatin-
specific events will be detectable in many tissues, and a
proportion detectable in only a restricted set. Thus, an
‘inappropriate’ cell line might still be informative, though
clearly not as desirable as the actual disease tissue.
Assay development will continue to be critical. The relatively
large number of cells currently required (1–10 m per assay)
increases the logistical and purification challenges. It seems
likely that improvements to the chromatin assays and to DNA
sequencing will allow lower cell numbers to be used. Currently
proof-of-principle experiments have worked for between
10 000 and 100 000 cells (29) for histone-modification-based
ChIP-seq. Computational analysis routines are also likely to
develop considerably over the coming years, and the decreases
in sequencing costs will allow deeply sequencing libraries to
become more routine. This will both allow better resolution
of weaker enrichment signals, and allow more sites to be
assessed for allele-specific biases.
Animal systems will continue to be informative since they
do not have the limitations of human studies surrounding
tissue accessibility, long generation times and a lack of
structured genetic crosses to study potential inheritance.
Next-generation sequencing allows a far deeper genetic under-
standing in model organisms, and the increasing number of
outbred or pseudo-outbred populations (30,31) will allow
experiments analogous to human disease cohorts.
It is still an open question which chromatin assay will be the
most informative for understanding individual differences.
Each assay’s relationship to other assays, both standard chro-
matin assays and other informative, related assays, such as
RNA-seq, still needs to be determined for individual-level
differences. More general assays such as DNaseI, FAIRE
and histone-modification-based ChIP capture more regulatory
sites, but their signal characteristics are less appropriate for
allele-specific analysis because of the more diffuse signal
around enriched regions. ChIP-seq of transcription factors is
highly focussed on a single protein and might miss important
biological phenomena in a cell, but it often can be better inte-
grated, for example with DNA motif analysis, and has stronger
allele-specific signals. In the short term, local expertise and
practicalities are likely to drive assay choice at least initially.
Another important aspect to explore is the difference of lym-
phoblastoid lines from their parent B cells in the context of
individual variation. A well-structured small ‘normal’
cohort, in which both many primary cells and lymphoblastoid
cell lines were derived and on which many chromatin assays
could be performed, would answer many of these questions.
We should consider creating such a baseline resource for the
correlation between chromatin patterns as being analogous
to the HapMap project creating a baseline SNP and a corre-
lation pattern between genetic variants. From such a baseline
resource, we would be able to determine the optimal assay
combination, at least for the studied cell type(s), and an
initial set of genetically influenced variable chromatin sites.
These studies would be invaluable for the planning and analy-
sis of any future disease study on chromatin effects, though it
is worth noting that unlike the genome-wide association scen-
ario, where the use of pooled controls have become common-
place, it is likely that study-specific control samples would
continue to be needed for these more experimentally demand-
ing assays.
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